Farmas USA

tranquilo siempre le puedes meter un corto a torrebruno que ese no falla...y en 9 minutos tienes un rojo negro al oro..

Resultado de la votacion en la reunion de accionistas
http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001437749%2D13%2D009070%2Etxt&FilePath=%5C2013%5C07%5C22%5C&CoName=CELSION+CORP&FormType=8%2DK&RcvdDate=7%2F22%2F2013&pdf=

Aprobado por gran mayoria otorgar a la direccion la capacidad de poder ejecutar un reverse split, si asi lo decidiera, en cualquier momento o antes de la proxima junta de accionistas del 2014.

"The proposal to grant discretionary authority to the Board of Directors to amend the Certificate of Incorporation of the Company, as amended, to effect, at any time on or prior to the date of the 2014 Annual Meeting of Stockholders ..."

CLSN

edito: no comprendo porque leo en foros usanos que estan aliviados por que el reverse split, de ejecutarse, seria en 2014.
O son unos necios manipuladores o soy yo que me he enredado con el ingles ...

Buenos días a tod@s.... Alquien conoce la pharma "Ocera therapeutics" (OCRX)??? Se ha fusionado con Tranzyme y bueno, no se que pensar.....

Gracias

Si el Viernes hubo mucho entrada retail, ayer Lunes el konkorde dice que institucionales entraron a saco, ya sea acumulando o cerrando cortos.
CTIX

O sea, que habría que subirse otra vez al carro, verdad?
Lo cierto es que el volumen del viernes y de ayer es muy elevado para este valor....

Un saludo

CTIX

Framus, ¿has visto lo de ARRY?
Hoy, a las 15:00 hora nuestra, presentan resultados para el ARRY-520 contra el asma...
Este ensayo lo terminaron en mayo, y ahora presentan los resultados...
Ayer en afters, el valor subió un 7% hasta los 5,96$....
Ahora, las posis me aparecen en 5,97-6,16....
Aunque no tiene mucho sentido el técnico, cuando hay news, te pego el gráfico, que sigue siendo muy bonito, y que espero que hoy quede aún más precioso....

Un saludo

ARRY

Bid 6 x Ask 6,16....

Qué buena pinta tiene para el pre, a la espera de os datos de ARRY-502....

ARRY

ARRY-502

According to the US Centers for Disease Control and Prevention (CDC), approximately 18.9 million adults in the United States have asthma, representing about 8.2% of the population. In addition, about 7.1 million children have asthma, which equates to about 9.5% of all US children.

Severe asthma affects approximately 10% of the asthmatic population. Currently, there are few treatment options for patients with severe asthma.

Array scientists are studying ARRY-502, an oral CRTh2 antagonist, as a treatment for patients with asthma, particularly those with severe disease. In preclinical models of allergic inflammation, ARRY-502 was found to have high anti-inflammatory activity. Array researchers also found that ARRY-502 provided robust, sustained pharmacodynamic activity and was found to be well tolerated by asthma patients in Phase 1 trials. All adverse events were mild.

In severe allergic asthma, there is emerging evidence suggesting that a greater presence of the mediator prostaglandin D2, or PGD2, and an upregulation of CRTh2, the biologically relevant receptor for PGD2-mediated allergic response, that is expressed on inflammatory cells, may play an important role in asthma symptoms such as coughing, difficult breathing, lower lung function and possibly exacerbations.

Based on the role of CRTh2 in mediating the actions of PGD2, Array scientists believe that the selective antagonism of CRTh2 presents an attractive therapeutic approach for the treatment of allergic diseases. There are selective antagonists of CRTh2 in various stages of clinical development with compounds currently being evaluated in Phase 2 studies in allergic rhinitis, asthma and eosinophilic esophagitis.

Array has completed recruitment of a 182-patient Phase 2a trial with ARRY-502 in mild to moderate persistent asthma. Array expects top-line results from this trial during the summer of 2013 and intends to seek a partner for further development of ARRY-502 in this large market disease indication.

Fuente: http://seekingalpha.com/article/1428191-part-2-will-array-biopharma-become-a-late-stage-biopharmaceutical-company